Figure 1.
Clinical study design for normal renal function and severe renal impairment groups (A) and end‐stage renal disease groups (B). A, 3 × 100‐mg itacitinib dose; CRU, clinical research unit; HD, hemodialysis; PK, pharmacokinetics.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.